Skip to main content

Table 13 Current ongoing early phase I/II trials with miscellaneous target inhibitors

From: Targeted therapy in advanced non-small cell lung cancer: current advances and future trends

Drug name

Mechanism of action

Clinical trial (phase)

Study design

Disease

ERBB2(HER2) inhibitors

Ado-trastuzumab emtansine

HER2-targeted antibody–drug conjugate

NCT03784599 (1/2)

Combination with osimertinib

EGFR mutant advanced NSCLC

Mobocertinib (TAk-788)

TKI targeting EGFR ex20ins mutations

NCT02716116 (1/2)

Combination with chemotherapy

EGFR and HER2 exon 20 insertion in advanced NSCLC

Poziotinib

EGFR, HER2 and HER 4 inhibitors

NCT03066206 (2)

Monotherapy

EGFR exon 20 and HER2 exon 20 mutated advanced NSCLC

trastuzumab deruxtecan

HER2-directed antibody–drug conjugate

NCT04644237 (2)

Monotherapy

HER2 mutated advanced NSCLC

SHP2 inhibitors

JAB-3068

SHP2 inhibitor

NCT03518554 (1)

Monotherapy

Advanced solid tumors including NSCLC

TNO155

SHP2 inhibitor

NCT03114319 (1)

Monotherapy and combination with Nazartinib

Advanced solid tumors including NSCLC

Other miscellaneous target inhibitors

Aliseritib

Selective aurora A kinase inhibitor

NCT04085315 (1/2)

Combination with Osimertinib

EGFR mutant NSCLC progressing after first line TKI

Anlotinib

VEGFR, FGFR, PDGFR, c-kit Inhibitor

NCT04165330 (1/2)

Combination with Nivolumab

Solid tumors including NSCLC

Apatinib

VEGFR-2 Inhibitor

NCT03811054 (2)

Combination with EGFR-TKI

EGFR mutant NSCLC progressing after first line TKI

APG-1252

Small molecule inhibitor of BCL2

NCT04001777 (1)

Monotherapy and combination with Osimertinib

EGFR mutant NSCLC

BMS-986205

IDO1 inhibitor

NCT02658890 (1/2)

Combination with Nivolumab and Ipilimumab

Advanced solid tumors including NSCLC

Eprenetapopt (Apr-246)

Stabilizes p53 in normal, functional structure

NCT04383938 (1/2)

Combination with Pembrolizumab

Advanced solid tumors including NSCLC

HBI-8000

Histone deacetylase inhibitor

NCT02718066 (1/2)

Combination with Nivolumab

Advanced NSCLC

Idelalisib

PI3K inhibitor

NCT03257722 (1/2)

Combination with Pembrolizumab

Advanced NSCLC with progression on first line therapy

IRX4204

Rexinoid, potent activator of RXRs

NCT02991651 (1)

Monotherapy and combination with Erlotinib

Advanced NSCLC with progression on two lines of therapy

NC318

IgG1 mAB specific for S15

NCT03665285 (1/2)

Monotherapy

Advanced solid tumors including NSCLC

Ningetinib (CT053PTSA)

Multi kinase inhibitor MET/HGFR

NCT03758287 (1/2)

Combination with Gefitinib

NSCLC with EGFR mutation and T790M negative

Nintedanib

PDGFR, FGFR, VEGFR inhibitor

NCT03377023 (1/2)

Combination with Nivolumab and Ipilimumab

Advanced or metastatic NSCLC

RGX-104

Liver X receptor agonist

NCT02922764 (1)

Monotherapy or in combination with immunotherapy or chemotherapy

Advanced solid tumors including NSCLC

Rucaparib

PARP inhibitor

NCT03845296 (2)

Monotherapy

Recurrent NSCLC

Selinexor

Exportin 1 inhibitor

NCT03095612 (1/2)

Combination with docetaxel

Advanced KRAS mutant NSCLC with progression on first line therapy

Selumetinib

MAPK inhibitor

NCT03392246 (2)

Combination with Osimertinib

Advanced EGFR mutant NSCLC

Ramucirumab

VEGFR2 antagonist

NCT03909334 (2)

Combination with Osimertinib

EGFR mutant NSCLC

Telaglenastat HCL

Glutaminase inhibitor

NCT03831932 (1/2)

Combination with Osimertinib

Advanced EGFR mutant NSCLC

Varlilumab

Anti CD27 antibody

NCT04081688 (1)

Combination with Atezolizumab

Advanced NSCLC with progression on first line therapy

Vorolanib

VEGFR/PDGFR inhibitor

NCT03583086 (1/2)

Combination with Nivolumab

Solid tumors including NSCLC

ZN-c3

WEE1 inhibitor

NCT04158336 (1/2)

Combination with Talazoparib or Pembrolizumab

Advanced solid tumors including NSCLC

RBN-2397

PARP7 inhibitor

NCT04053673 (1)

Monotherapy

Advanced solid tumors including NSCLC